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Abstract
The two presenilin-1 (PS1) and presenilin-2 (PS2) homologs are the catalytic core of the c-secretase complex, which has a major role in cell
fate decision and Alzheimer’s disease (AD) progression. Understanding the precise contribution of PS1- and PS2-dependent c-secretases to the
production of b-amyloid peptide (Ab) from amyloid precursor protein (APP) remains an important challenge to design molecules efficiently
modulating Ab release without affecting the processing of other c-secretase substrates. To that end, we studied PS1- and PS2-dependent sub-
strate processing in murine cells lacking presenilins (PSs) (PS1KO, PS2KO or PS1-PS2 double-KO noted PSdKO) or stably re-expressing
human PS1 or PS2 in an endogenous PS-null (PSdKO) background. We characterized the processing of APP and Notch on both endogenous
and exogenous substrates, and we investigated the effect of pharmacological inhibitors targeting the PSs activity (DAPT and L-685,458). We
found that murine PS1 c-secretase plays a predominant role in APP and Notch processing when compared to murine PS2 c-secretase. The inhi-
bitors blocked more efficiently murine PS2- than murine PS1-dependent processing. Human PSs, especially human PS1, expression in a PS-
null background efficiently restored APP and Notch processing. Strikingly, and contrary to the results obtained on murine PSs, pharmacological
inhibitors appear to preferentially target human PS1- than human PS2-dependent c-secretase activity.
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Introduction
Presenilins 1 and 2 are homologous polytopic proteins that represent
the catalytic subunits of the c-secretase complex. The assembly and
activation of the c-secretase is achieved by the association of either
PS1 or PS2 [1] with three other membrane proteins: nicastrin (Nct),
anterior pharynx defective 1 (Aph1a or Aph1b in humans; Aph1a,
Aph1b or Aph1c in rodents [2]) and presenilin enhancer 2 (Pen-2),
giving rise to four and six different c-secretases in humans and
rodents, respectively. The c-secretase is responsible for the cleavage
of up to 90 type I integral membrane proteins [3, 4] that have previ-
ously undergone an ectodomain shedding by processing at a cleavage
site close to their transmembrane domain [5]. This results in the gen-
eration of a membrane-anchored C-terminal fragment (CTF), which is
subsequently cleaved by the c-secretase within its transmembrane
domain to generate a truncated membrane stub and a soluble intra-
cellular domain (ICD). The APP and the Notch receptor are the pre-
dominant substrates of c-secretase (PSs) [6]. Their processing is of
critical importance in AD aetiology and in cell proliferation, develop-
ment and tissue homoeostasis. The onset and progression of AD
relies on the release of various Ab generated by the c-secretase cleav-
age of APP [7]. Ab is the main component of the senile plaques found
in brains of AD patients [8]. Notch signalling is triggered by the
c-secretase release of its intracellular domain (NICD) that exerts
essential functions during development [9].
Much attention in AD research has focused on the c-secretase-
mediated cleavage of the amyloidogenic CTF of APP (b-CTF or C99)
that generates the intracellular domain of the protein (AICD) and the
Ab peptide [10]. To block amyloid deposition and the formation of
senile plaques, many pharmacological approaches have been designed
to target the c-secretase activity, but clinical trials of c-secretase
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inhibitors or modulators have been halted due to severe adverse effects
[11]. These adverse effects were primarily due to the concomitant inhi-
bition of the c-secretase-dependent cleavage of Notch (NotchDE) [12]
producing NICD, thus precluding its signalling critical in cell fate deci-
sion/cell regeneration in the adult organism [13]. To note, Notch pro-
tein also acts as a tumour suppressor, leading to an increased risk of
cancers when its processing is inhibited [14], in accordance with
adverse effects observed in clinical trials testing c-secretase inhibitors.
In this context, our primary goal was to investigate the respective
contribution of PS1- and PS2-dependent c-secretases in the cleavage
of their principal substrates, APP and Notch. Discrimination of PS1 and
PS2 c-secretases activities has remained elusive but has gained consid-
erable interest with very recent studies showing that PS1 and PS2
c-secretases can be discriminated by their subcellular localization, with
an impact on substrate processing [15, 16]. However, the understand-
ing of substrate specificities of PS1 and PS2 c-secretases and their
functional relevance remains very limited. To investigate the precise
contribution of PS1 and PS2 to APP and Notch processing, we used a
homologous approach [17] allowing to directly compare the processing
of APP and Notch by a reporter assay measuring the release of AICD
and NICD. The transactivation of reporter genes is achieved by the pres-
ence of a Gal4-VP16 sequence fused to AICD or NICD, efficiently acti-
vating a response element Gal4RE coupled to a luciferase reporter
gene. These tags (Gal4-VP16) were previously shown not to interfere
with APP and Notch processing and to allow a highly specific and sensi-
tive detection of the processing of both substrates by c-secretase [17],
granting the comparison of the two cleavages in a standardized system.
We carried out our study in mouse embryonic fibroblasts (MEFs) either
expressing both PSs (PS wild-type; PS1+/+PS2+/+ noted PS+/+), none
of them (PS double-knockout; PS1/PS2/ referred to as PSdKO)
or only one (PS1 or PS2 single-KO; PS1/PS2+/+ and PS1+/+PS2/
 referred to as PS1KO and PS2KO, respectively). We also used cells
stably expressing human PS1 or PS2 (rPS1wt, rPS2wt) in an endoge-
nous PS-null background (PSdKO) as well as cells stably expressing
catalytically inactive forms of human PS1 or PS2 (rPS1DA, rPS2DA) in
the same background [18]. We tested in our models two well-character-
ized pharmacological c-secretase inhibitors: DAPT [19] and L-685,458
[20] (noted L-685), to study their effects on PS1- and/or PS2-
dependent processing of APP and Notch.
Our results show that murine (endogenous) PS1, but not PS2, is
strongly involved in the processing of APP and Notch. Absence of
PS1 (PS1KO) provokes a drastic reduction of APP and Notch cleav-
ages, which are restored by the expression of human PS1 (rPS1wt).
These observations are consistent with previously published data [21,
22] underlining the predominant role of PS1 in c-secretase-dependent
substrate processing. Strikingly, our results further indicate that phar-
macological c-secretase inhibitors differently affect PS1 and PS2
c-secretases. More precisely, endogenous murine PS1 (in PS2KO)
appears resistant to the pharmacological inhibition while endogenous
murine PS2 (in PS1KO) is sensitive to it. On the contrary, human PS1
is more affected by inhibitory treatments than its homolog PS2 (in
rPS1wt and rPS2wt, respectively). Finally, the results obtained with
the catalytically inactive human PSs (rPSDA) suggest that PS2 may
have a role in APP cleavage independently of its enzymatic activity,
whereas PS1-dependent cleavage requires a native catalytic site.
Materials and methods
Cell lines and cell culture
Mouse embryonic fibroblasts (MEFs) wild-type (PS+/+) and knockout
cell lines for PS1 (PS1KO), PS2 (PS2KO) or both (PSdKO) were a kind
gift of B. De Strooper (KUL, Leuven, Belgium). Original plasmids
expressing wild-type or mutant forms of human PS1 and PS2 and len-
tiviral constructs used to produce stable rescued cell lines from MEFs
PSdKO (rPS) were described previously [18]. MEFs cells were cultured
in DMEM-F12 media (Life Technologies, Carlsbad, CA, USA). All media
were supplemented with 10% of foetal bovine serum (FBS) (Thermo
Scientific, Rockford, IL, USA) and penicillin–streptomycin solution (10
units–10 lg). Puromycin (2.5 lg/ml) was used for the selection and
maintenance of rPS cells. All cell cultures were maintained at 37°C in a
humidified atmosphere (5% CO2).
Chemicals and reagents
Reagents for Western blotting and BCA protein assay kit were from
Pierce (Rockford, IL, USA), membranes and ECL+ from GE Health-
care (Little Chalfont, UK). Primary antibodies anti-PS1 and anti-PS2
were from Cell Signaling (Danvers, MA, USA), anti-VP16 and anti-
Notch1 were from Abcam (Cambridge, UK), and anti-actin and anti-
tubulin antibodies and the fluorescent nucleic acid stain DAPI were
obtained from Sigma-Aldrich (St Louis, MO, USA). Primary antibody
directed against APP-CTF was kindly received from N. Sergeant
(INSERM, Lille, France). Secondary antibodies coupled to peroxidase
were obtained from Amersham Bioscience (Uppsala, Sweden). The
applied dilutions for each antibody were according to the manufac-
turer’s instructions. Alexa-labelled secondary antibodies were obtained
from Life Technologies. Fluorescent mounting medium was from
DAKO (Agilent Technologies, Santa Clara, CA, USA). TRIzol reagent
and CompleteTM protease inhibitor cocktail were from Roche (Basel,
Switzerland). The cDNA synthesis kit and iQ SYBR Green Supermix
were from Bio-Rad (Hercules, CA, USA).
Western blotting
Cells were rinsed and scraped off in PBS and centrifuged for 5 min.
at 7.000 g. Pellets were sonicated in lysis buffer (125 mM Tris pH
6.8, 20% glycerol, 4% SDS) with CompleteTM protease inhibitor cock-
tail. Protein concentration was determined using the BCA protein
assay kit. Fifteen to forty micrograms of protein were heated for
10 min. at 70°C in loading buffer (lysis buffer containing 0.5 M DTT
and staining SeeBlue Plus2, Life Technologies), loaded and separated
onto 4–12% NupageTM bis-Tris gels (Life Technologies), and then
transferred for 2 hrs at 30V onto nitrocellulose membranes. After
blocking (5% non-fat milk in PBS), membranes were incubated over-
night at 4°C with the primary antibodies, then washed, and incubated
with the secondary antibodies coupled to peroxidase prior to ECL
detection. Primary antibodies are as follows anti-PS1 (1:1.000), anti-
PS2 (1:1.000), anti-VP16 (1:500), anti-Notch1 (1:500), anti-APP-CTF
(1:5000), anti-actin (1:3000) or anti-tubulin (1:3000). Secondary anti-
bodies are as follows anti-mouse (1:10.000) or anti-rabbit (1:10.000).
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RNA preparation, qPCR and RT-PCR
The RNAs were extracted from cells and tissues in TRIzol reagent
and reverse-transcribed using an iScript cDNA synthesis kit. Real-
time qPCR analyses were performed on 2 ng of cDNA template using
iQ SYBR Green Supermix in an iCycler IQ multicolour Real-Time PCR
detection system. qPCR conditions were typically 95°C for 30 sec.,
followed by 40 cycles of 30 sec. at 95°C, 45 sec. at 60°C and
15 sec. at 79°C and ended by 71 cycles of 30 sec. at 60°C. The rel-
ative changes in the target gene-to-GAPDH mRNA ratio were deter-









Cells were seeded and transfected on 12-well plates. Forty eight hours
after transfection, cells were rinsed twice with Opti-MEM and fixed with
4% paraformaldehyde (PFA) for 15 min. After three washes in PBS,
cells were permeabilized with PBS1X/0.3% Triton 100-X for 30 min.
and blocked in PBS1X/FBS5%/0.1% Triton 100-X for 30 min. Primary
antibodies (anti-PS1, PS2 and VP16) were prepared in the blocking
solution (1:100) and incubated O/N at 4°C. After three washes in PBS,
cells were incubated with secondary antibody (goat antimouse Alexa
594 and goat antimouse Alexa 488, 1:500 in blocking solution) and
DAPI (1:2000) for 1 hr at 4°C. After three washes in PBS, cells were
stored in PBS-azide 0.1% at 4°C. Pictures were taken with an Olympus
Fluoview confocal microscope (Olympus America Inc., Center Valley,
PA, USA).
DNA constructs
The pCDNA3.1 plasmid bearing the C99-GVP construct, the pCS2 har-
bouring NotchDE-GVP, the Gal4RE Firefly luciferase reporter gene
(pG5E1B-luc) and the Renilla luciferase reporter vector (phRG-TK) have
been previously described [17, 23].
Cell transfection
MEFs were transfected 24 hrs after seeding using Trans-IT2020
(Mirus Bio Corporation, Madison, WI, USA). Transfection was per-
formed according to the manufacturer’s instructions. Cell lysates were
harvested 48 hrs after transfection for analysis.
Pharmacological treatments
Two specific c-secretase inhibitors were used: N-[N-(3,5-difluorophena-
cetyl)-L-alanyl]-sphenylglycine t-butyl ester or DAPT (Calbiochem,
Camarillo, CA, USA), and L-685,458 (Sigma-Aldrich), noted L-685. MEFs
cells were treated with 0.25, 1 or 10 lM of DAPT and with 10 or
20 lM of L-685. Cells were harvested 16 hrs after pharmacological
treatments for analysis.
Luciferase
Cells were cotransfected in a 1:1:1 ratio with pG5E1B-luc, phRG-TK and
either pCDNA3.1-C99-GVP or pCS2-NotchDE-GVP to quantify the
release of AICD-GVP or NICD-GVP, respectively. Forty eight hours after
transfection, cells were rinsed with PBS and incubated with the reporter
lysis buffer (Promega, Madison, WI, USA) for 15 min. at room tempera-
ture. Firefly and Renilla luciferase activities were measured using the
Dual-Glo Luciferase Assay System on a Sirius luminometer (Berthold,
Pforzheim, Germany). Luciferase activity corrected for transfection effi-
ciencies was calculated as the Firefly/Renilla luciferase ratio.
Statistical analysis
The number of samples (n) in each experimental condition is indicated
in the figure legends. Statistical analyses were performed using Graph-
Pad Prism software (GraphPad Software, La Jolla, CA) by ANOVA fol-
lowed by Bonferroni’s multiple comparison tests.
Results
Endogenous murine PS1 and PS2 involvement in
C99-GVP and NotchΔE-GVP cleavage
The PSs expression profile was monitored in each MEFs cell line used
for this study; PS+/+, PSdKO, PS1KO and PS2KO by Western blotting
with antibodies directed against the CTF of PS1 or PS2 (Fig. 1A). It
appeared that absence of a PS can be compensated by an increased
expression of the other, especially in the case of PS2 levels increased
in the absence of PS1. This was confirmed by qPCR, showing that
PS2 mRNA levels are higher (+200%) in PS1KO than in PS+/+ cells
(Fig. 1B). Interestingly, absence of PS2 had only moderate effects on
PS1 transcription (+40%). Cross-regulation of PSs expression has
already been reported [24] and must be kept in mind here for the
interpretation of the respective contribution of PS1 and PS2 to APP
and Notch processing.
To investigate the particular role of PS1 and PS2 in substrate
cleavage, we expressed C99-GVP (Fig. 1C) and NotchDE-GVP
(Fig. 1D) constructs in our MEFs. These constructs have been devel-
oped to allow direct comparison of APP and Notch processing in a
defined cellular context [17]. The release of APP and Notch intracellu-
lar domains (AICD and NICD, respectively) from exogenous
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Fig. 1 Characterization of PS wild-type, single and double-knockout MEFs cell lines. (A) Western blot of cell lysates from PS+/+, PSdKO, PS1KO and
PS2KO MEFs revealed with anti-PS1-CTF and anti-PS2-CTF antibodies. Actin was used as a protein loading control. Results exhibited the presence
of endogenous PS1-CTF in PS2KO, and of PS2-CTF in PS1KO cells. (B) qPCR quantification of endogenous PS1 and PS2 mRNA levels in wild-type
and single-KO conditions. Results (means  S.E.M.) are represented as percentages of PS+/+ signals. *P < 0.05, **P < 0.01 versus PS+/+, n = 5.
(C) Immunocytochemistry (left panel) was performed in PS+/+, PSdKO, PS1KO and PS2KO MEFs transfected with the C99-GVP construct. Cells
were immuno-stained for VP16-tag (green) and DAPI (blue). Stainings have been analysed by confocal microscopy to generate z-stack images. Wes-
tern blotting (right panel, top) was performed with an antibody directed against the VP16 domain of the GVP fusion protein to check the transfection
efficiency of C99-GVP construct, and quantification of AICD-GVP release (right panel, bottom) was monitored by luciferase activity. Results
(means  S.E.M.) are represented as percentages of PS+/+ signals. *P < 0.05, ***P < 0.001 versus PS+/+, n = 9 in three independent experi-
ments. (D) Left, immunocytochemistry was performed in PS+/+, PSdKO, PS1KO and PS2KO MEFs transfected with the NotchDE-GVP construct and
analysed as described in (C). Right, Western blotting with an antibody directed against VP16 domain of the GVP fusion protein (top) and quantifica-
tion of NICD-GVP release (bottom). Results (means  S.E.M.) are represented as percentages of PS+/+ signals. **P < 0.01, ***P < 0.001 versus
PS+/+, n = 9 in three independent experiments. Scale bar: 20 lm.
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substrates (C99-GVP and NotchDE-GVP) was measured by a Gal4
reporter gene assay. We first verified by immunocytochemistry using
an antibody directed against the VP16 domain of the GVP fusion pro-
tein that they were properly expressed and localized in the different cell
lines. Results showed that the fusion proteins were efficiently
expressed with a consistent subcellular localization in the cells (Fig. 1C
and D). Moreover, Western blotting with the same antibody directed
against VP16 showed that the transfection efficiency of both C99-GVP
and NotchDE-GVP constructs was comparable in all cell types (Fig. 1C
and D). The specificity of the signals detected around 35 kDa and
100 kDa for C99-GVP and NotchDE-GVP, respectively, was checked by
comparison of non-transfected versus transfected cells (Fig. S1).
Luciferase assays indicated that the c-secretase cleavages of both
C99-GVP and NotchDE-GVP were abolished in PSdKO, as expected.
To note, a low residual activity was measured for C99-GVP in PSdKO
cells, likely due to a basal leaking of C99 constructs in the nuclear
compartment (Fig. 1C). We observed a significant decrease in the
luciferase activity especially for NotchΔE-GVP in PS1KO cells, while
in PS2KO cells, the signals were not significantly different from those
measured in PS+/+ cells. This indicates that endogenous murine PS1
is predominantly involved in AICD-GVP and NICD-GVP production.
Rescue of APP and Notch cleavage by re-
expression of human catalytically active PSs in a
PS-null background
Mouse embryonic fibroblasts stably re-expressing human wild-type or
catalytically inactive PSs (rPS1/2wt, rPS1/2DA) in a PSdKO back-
ground have been previously described [18]. We monitored human
PSs expression and activation by Western blotting (Fig. 2A and B) in
these cells. Both PS1 and PS2-CTFs were detected in PS+/+, as well as
in rPS1wt and rPS2wt cells, respectively. These CTFs were absent in
the DA mutants, where an accumulation of full-length PSs (around
45 kDa) is observed. This is characteristic of catalytically inactive
forms of PSs that do not undergo endoproteolytic activation. The
expression of both C99-GVP and NotchDE-GVP constructs was verified
in rescued cell lines using immunocytochemistry with the antibody
directed against the VP16 domain of the GVP fusion protein. Both
fusion proteins were efficiently expressed with a consistent subcellular
localization in the cells (Fig. 2C and D). Western blotting showed that
the transfection efficiency of both C99-GVP and NotchDE-GVP con-
structs was comparable in all cell types (Fig. 2C and D).
We measured the effect of PSs re-expression on C99-GVP and
NotchΔE-GVP processing by c-secretase (Fig. 2C and D). C99-GVP
cleavage observed in rPS1wt was comparable to the one measured
in PS+/+ cells (Fig. 2C). In rPS2wt cells, the restoration appears
less efficient but the signal triggered by C99-GVP cleavage is not
significantly different from PS+/+ cells (Fig. 2C). NotchΔE-GVP pro-
cessing was lower in PSs rescued cells when compared to PS+/+
cells, although significantly restored when compared to the PSdKO
control cells (Fig. 2D). To note, the levels of human PS2 expression,
higher than endogenous PS2 levels, might lead to an overestimation
of the PS2-dependent c-secretase activity in the PS2-rescued cells
(Fig. 2A). The inactivation of PS1 catalytic activity (rPS1DA)
abolished the cleavage of both substrates (Fig. 2C and D). In
rPS2DA cells, a residual luciferase activity was measured in C99-
GVP expressing cells but it is non-significant when compared to
PSdKO controls.
Effects of c-secretase inhibitors on APP and
Notch processing in PS1 or PS2 expressing cells
We used these different cell lines to measure the effects of two well-
documented and specific c-secretase inhibitors that bind the active
complex: DAPT [19] and L-685,458 (noted here L-685) [25]. We first
treated MEFs PS+/+, single and double-KO cells with increasing
concentrations of the two inhibitors, and measured the cleavage of
C99-GVP and NotchΔE-GVP under these conditions (Fig. 3A and B).
Treatments with both inhibitors repressed C99-GVP processing in a
dose-dependent manner in PS+/+ cells. To note, they were even more
efficient towards NotchΔE-GVP processing. No inhibition was mea-
sured in PSdKO cells, confirming the specific action of the treatments
on PSs-dependent c-secretase activity. Results obtained in the single-
KO cells showed that c-secretase inhibitors were much more efficient
on endogenous murine PS2 than PS1, as measured in PS1KO versus
PS2KO cells, respectively. Maximal inhibition of C99-GVP cleavage
reached a plateau for both inhibitors at concentrations around 10-
20 lM in PS2-expressing cells. A much lower and globally non-signifi-
cant inhibition (25%) was measured in PS1-expressing cells (all these
values are summarized in Table S1). A similar pattern was observed
for NotchΔE-GVP processing, with even greater inhibitory effects in
PS2-expressing cells at high concentrations (around 80%).
Same experiments were carried out in PSdKO cells re-expressing
the wild-type or catalytically inactive human PS1 or PS2 (Fig. 4A and
B). Strikingly, the c-secretase inhibitors were efficient in rPS1wt cells,
blocking both C99-GVP and NotchΔE-GVP processing, with maximal
inhibitory effects of 57% and 68%, respectively. They significantly
blocked NotchΔE-GVP cleavage in rPS2wt cells (55% of inhibition at
the highest concentrations), but were much less efficient on C99-GVP
processing (see Table S1), even if an inhibitory trend was observed.
As expected, the c-secretase inhibitors were inactive in cells express-
ing rPS1DA and rPS2DA mutants.
All these results were obtained on the processing of exogenous
APP and Notch substrates. We also addressed the effects of DAPT and
L-685 on endogenous APP and Notch (Fig. S2). Treatments with DAPT
and L-685 triggered the accumulation of the endogenous C-terminal
fragments of APP and Notch, due to inhibition of their processing by
c-secretase. In PS1KO cells, we observed a noticeable accumulation of
CTFs upon treatment, especially for APP-CTFs. PS2KO cells exhibited
no apparent sensitivity to inhibitors, except for DAPT on APP cleavage
(Fig. S2A). In rescued cell lines, both inhibitors exerted an effect on
cleavages of APP and Notch in rPS1 cells, while in rPS2 cells, the inhi-
bitors showed no apparent effect on the accumulation of C-terminal
fragments (Fig. S2B). Overall, inhibitory treatments seemed to reveal
comparable effects on exogenous versus endogenous substrates,
depending on the nature of PSs they are targeting (murine or human).
Importantly, this is not due to an altered subcellular distribution of res-
cued PSs versus endogenous ones, as shown in Fig. S3.
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Fig. 2 Characterization of rescued cell lines expressing human PSs. (A) Cell lysates from PS+/+, PSdKO, rPS1wt and rPS1DA MEFs were analysed
by Western blotting. The presence of PS1, full-length and CTF, was detected by the anti-PS1-CTF antibody. Tubulin was used as a protein loading
control. Results exhibited the restauration of full-length PS1 expression in both rescued models, with an active form (PS1-CTF) only in rPS1wt. (B)
Cell lysates from PS+/+, PSdKO, rPS2wt and rPS2DA MEFs were analysed by Western blotting for the presence of PS2, full-length and CTF, using
the anti-PS2-CTF antibody. Tubulin was used as a protein loading control. Results exhibited the restauration of PS2-full-length expression in both
rescued models, with an active form (PS2-CTF) only in rPS2wt. (C) Immunocytochemistry was performed in rPS1wt, rPS1DA, rPS2wt and rPS2DA
MEFs transfected with the C99-GVP construct (left panel). Cells were immuno-stained for VP16-tag (green) and DAPI (blue). Stainings have been
analysed by confocal microscopy to generate z-stack images. Western blotting (right panel, top) was performed with an antibody directed against
the VP16 domain of the GVP fusion protein to check the transfection efficiency of C99-GVP construct, and quantification of AICD-GVP release (right
panel, bottom) was monitored by luciferase activity. Results (means  S.E.M.) are represented as percentages of PS+/+ signals. ***P < 0.001 ver-
sus PS+/+, n = 9 in three independent experiments. (D) Immunocytochemistry was performed in rPS1wt, rPS1DA, rPS2wt and rPS2DA MEFs trans-
fected with the NotchDE-GVP construct (left panel) and analysed as described in (C). Right, Western blotting with the VP16 antibody (top) and
quantification of NICD-GVP release (bottom). Results (means  S.E.M.) are represented as percentages of PS+/+ signals. **P < 0.01,
***P < 0.001 versus PS+/+, n = 9 in three independent experiments. Scale bar: 20 lm.
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Fig. 3 Effect of c-secretase inhibitors on
AICD-GVP and NICD-GVP release in wild-
type, single and double-knockout cell lines.
(A) MEFs PS+/+, PSdKO, PS1KO and
PS2KO were cotransfected with C99-GVP
construct and reporter genes and were
treated for 16 hrs with DAPT 250 nM,
1 lM, 10 lM or L-685 10 lM, 20 lM. (B)
Wild-type and knockout MEFs were
cotransfected with NotchDE-GVP construct
and reporter genes and were treated as
described in (A). Quantification of AICD-
GVP (A) and NICD-GVP (B) release was
performed by measurement of luciferase
activity. Results (means  S.E.M.) are
represented as percentages of signal mea-
sured in PS+/+ non-treated (NT) cells.
*P < 0.05, **P < 0.01, ***P < 0.001 ver-
sus corresponding NT cell type in each
condition, n = 9 in three independent
experiments.
Fig. 4 Effect of c-secretase inhibitors on
AICD-GVP and NICD-GVP release in res-
cued cells expressing human wild-type or
mutated PS1 or PS2. (A) MEFs PSdKO res-
cued with PS1/PS2 wt/DA were cotrans-
fected with C99-GVP construct and
reporter genes and were treated for 16 hrs
with DAPT 250 nM, 1 lM, 10 lM or L-685
10 lM, 20 lM. (B) Rescued cell lines were
cotransfected with NotchDE-GVP construct
and reporter genes and were treated as
described in (A). Quantification of AICD-
GVP (A) and NICD-GVP (B) release was
performed by measurement of luciferase
activity. Results (means  S.E.M.) are rep-
resented as percentages of signals mea-
sured in non-treated (NT) rPS1wt or
rPS2wt cells, respectively. *P < 0.05,
**P < 0.01, ***P < 0.001 versus corre-
sponding NT cell type, n = 9 in three inde-
pendent experiments.
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Discussion
The physiological and pharmacological properties of the different
c-secretase complexes are poorly understood, although several lines
of evidence indicate that they might be differentially distributed in tis-
sues and differentially involved in substrate processing [15, 16, 26].
Different c-secretase subunits assemble in at least four human and
six rodent complexes, differing by the presence of PS1 or PS2 and
Aph1A or Aph1B (or Aph1C in rodents) with repercussions on the
complex’s properties. For instance, the biochemical and physiological
consequences of genetically reduced c-secretase activity in different
Aph1KO models were reported to be divergent and tissue specific [2].
More recently, PS1 and PS2 were reported to target c-secretase com-
plexes in distinct cellular compartments [15, 16]. The localization of
the PS1 or PS2 c-secretase complex determines substrate specificity,
at least for APP processing [15]. These very fundamental observa-
tions raise the following points that we addressed in the present
study: (i) are PS1 and PS2 c-secretases differentially involved in the
cleavage of their two major substrates, APP and Notch and (ii) do
pharmacological inhibitors differentially target PS1 and PS2
c-secretases. We dissected the contribution of murine and human
PS1 c-secretases in APP and Notch processing, and strikingly, we
found that well-characterized c-secretase inhibitors differentially tar-
get human and murine c-secretases.
In our study, we compared the c-processing of APP and Notch
using a sensitive transactivation assay that measures the release of
AICD and NICD, respectively [17]. In this set-up, AICD and NICD
harbour a Gal4-VP16 fusion sequence that allows a very sensitive and
specific detection of AICD and NICD production by a Gal4 transactiva-
tion assay. The tagging of the APP and Notch proteins was previously
shown not to affect their processing by c-secretase. The big
advantage of this assay is to allow a direct comparison of the two
cleavages in a homologous system, when compared to other reporter
gene assays developed to measure APP and Notch processing
independently [18].
To address the exact contribution of PS1 and PS2 c-secretases to
substrate processing, we used PS(s) KO MEFs cells [27]. Most of the
cell types, including neurons, express both PS1 and PS2 [26], making
impossible to analyse the respective contribution of PS1 and PS2 in
c-secretase activity measured in cells. In addition, the PSdKO MEFs
cells allowed us to generate cell lines stably expressing different
forms of human PS1 and PS2 proteins in a PS-null background. In
vitro c-secretase assays reported in our previous studies [18] indicate
that c-secretase activity was functionally restored in these cells. This
is confirmed here by the presence of activated PSs in rescued cells,
attested by the presence of the PSs CTFs generated by endoproteoly-
sis in the activation step of the c-secretase [28]. These cellular mod-
els allowed us to analyse the catalytic properties of human and
murine c-secretases differing only by the PSs subunit. This cannot be
achieved by overexpression studies, as only a small pool of the over-
expressed exogenous PSs is activated and incorporated in active
c-secretases [29].
We found that c-secretase activity is finely tuned in cells and
has to be kept in a defined range, as deficiency in one PS is
compensated by an increased expression of the other. PS2
overexpression was already shown to down-regulate PS1 expres-
sion [24]. Here, we found that the absence of PS1 strongly up-
regulates PS2 at the transcriptional level. This could suggest in
another way that transcription of PS2 is down-regulated by PS1
in physiological conditions. The significance of this observation in
cell physiology and the underlying mechanisms of PS1-dependent
transcriptional regulation of PS2 are unknown and await further
investigation. Still, it raised an important point for the interpreta-
tion of our study. Indeed, our single PSKO MEFs cells are very
useful to analyse and compare the enzymatic properties of PS1
and PS2 c-secretases, but conclusions about the respective con-
tribution of these c-secretases to substrate processing can hardly
be extrapolated.
Several studies have reported a lower activity of PS2 c-secretases
compared to PS1 c-secretases [16, 30, 31]. Our work confirms, both
in single-KO and rescued cells, that APP substrates are more effi-
ciently processed by PS1 than by PS2 and this is in line with pub-
lished results showing a predominant implication of PS1 in the
c-secretase activity [21, 22, 32, 33]. However, we observed that PS2-
expressing cells still efficiently cleave C99-GVP. This was also previ-
ously reported [34] and raises the hypothesis that lower cleavage of
APP by PS2 c-secretase could be related to a reduced availability of
APP-CTFs for PS2 c-secretase, rather than a poor affinity. Indeed,
PS2 c-secretases are enriched in late endosomes and lysosomes
[15], and APP might be efficiently processed in cells along trafficking
through the secretory pathway and at the plasma membrane [16]
before reaching endosomal compartments.
In PSdKO cells, we found the background signal in C99-GVP
expressing cells to be higher than the NotchΔE-GVP signal.
Although very low (10% of the signal measured in PS+/+ cells),
this would suggest that a PS-independent c-secretase activity
towards C99-GVP exists in these cells. Previous reports indicated
the possible existence of PS-independent c-secretase activity,
either by in vitro c-secretase assay or by measurement of Ab pro-
duction in PSdKO cells [35, 36]. PS-independent c-secretase activ-
ity has been a matter of controversy [37] but it could suggest
that the basal activity of C99-GVP observed in PSdKO results from
a processing not operated by PSs. However, the C99-GVP con-
struct was previously tested in PSs deficient cells (PSdKO mouse
blastocyst-derived BD8 cell line) and did not exhibit any signal
[17]. Thus, the signal measured in PSdKO cells is more likely to
result from leaking of a small portion of non-cleaved C99-GVP to
the nucleus, rather than from a proteolysis of C99-GVP.
One important asset of our model is to overcome biases encoun-
tered by simple PSs overexpression [38–40]. The major biases are
abundant levels of inactive PSs and mislocalization of PSs in cells.
Here, the rescued cell lines showed no accumulation of inactive (full-
length) PSs and, importantly, a subcellular localization of PSs in line
with recent studies [15, 16] showing different cellular distribution of
PS1 and PS2 c-secretases. In addition, no differences were observed
between endogenous (murine) and rescued (human) PS1 or PS2 dis-
tributions (Fig. S1).
Regarding PS1 and PS2 activities, we made an unexpected
observation. We detected a residual c-cleavage of C99-GVP with
8 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
the catalytically inactive PS2DA mutant. This was not observed
with the PS1DA mutant. No active endoproteolysed hPS2 was
detected in the rPS2DA cell line. One hypothesis could be that the
presence of non-cleaved PS2 favours an unspecific transactivation
by C99-GVP (e.g. without c-cleavage, or by cleavage by an
unknown protease). Alternatively, studies have reported the forma-
tion of complexes between APP and PS2, but not PS1, in trans-
fected cells [41], indicating specific interactions between APP and
PS2 that could explain this observation. Finally, full-length PS2
could integrate the c-secretase complex and display partial
c-secretase activity. This last point has never been illustrated so
far and is purely hypothetical, and in vitro assays did not show a
restoration of c-secretase activity by rPS2DA mutants [18],
strongly suggesting that the effects observed with rPS2DA cells
here might be independent of C99-GVP cleavage.
Our most striking observation is that specific and well-described
inhibitors differentially inhibited c-secretase complexes containing
either endogenous (murine) or rescued (human) PSs. DAPT [19]
was found to specifically bind to PS1 (not PS2) CTFs in human
HeLa cells, to a domain distinct from the catalytic site or substrate
binding site [42]. L-685 is a transition state analogue inhibitor [25]
directed to the active site of the c-secretase, that binds to PS1 and
PS2 proteolytic fragments from human HeLa cells and mouse N2a
neuroblastoma [43]. We found that DAPT efficiently blocks the
cleavage of C99-GVP and NotchDE-GVP in cells expressing human
PS1, in agreement with the study of Dovey and collaborators [19].
However, DAPT only efficiently blocked the processing of NotchDE-
GVP in cells expressing human PS2, indicating that even at
sub-micromolar concentrations (i) DAPT blocks PS2-dependent
c-secretase activity (ii) the inhibitory effects of DAPT on APP and
Notch processing can be discriminated. The first observation might
be in contradiction with data indicating that DAPT does not bind to
PS2. We suggest here that DAPT efficiently inhibits and thus proba-
bly binds to human PS2, but might bind preferentially to human
PS1 in cell extracts where both PS1 and PS2 are expressed. DAPT
was found to inhibit more efficiently Notch processing than APP
processing in human PS2-expressing cells. To note, inhibition of
Notch signalling by DAPT is documented [44]. The same observa-
tions hold true for L-685, a competitive c-secretase inhibitor. Thus,
differential effects of inhibitors on APP and Notch processing do
not depend on their inhibitory mechanism (competitive/non-
competitive), but rather on the presence of human PS1 or PS2 in
the c-secretase complex. Strikingly, the inhibitory effects of DAPT
and L-685 were opposite on c-secretases containing murine PS1 or
PS2 and c-secretases containing human PS1 or PS2. Both DAPT
and L-685 efficiently inhibited APP and Notch processing only in
PS1KO MEFs cells, thus solely expressing endogenous PS2. They
inhibited to a greater extent NotchDE-GVP than C99-GVP cleavage
(around 80% and 60%, respectively).
Most of these observations hold true for endogenous substrates
(Fig. S2). In single-knockout cell lines, inhibitors were able to block
efficiently the murine PS2-dependent processing of APP-CTF, and
slightly the one of NotchDE. In PS2KO cells, excepted DAPT inhibition
of APP-CTF processing that has also been observed as significant at
1 lM concentration on C99-GVP, both inhibitors appeared to be
poorly efficient on murine PS1-dependent activities. In rescued cell
lines, both DAPT and L-685 distinctly inhibited human PS1-dependent
processing to a greater extent that human PS2-dependent process-
ing, for both APP-CTF and NotchDE.
The different pharmacological properties of c-secretase con-
taining murine or human PSs have not been reported so far to
our best of knowledge. They could result from intrinsic proper-
ties (domains, structure and folding) that are different between
human and rodent PSs. One other hypothesis could be that the
catalytic properties of rodent c-secretases differ from human
c-secretases because of differences in the structure and compo-
sition of the subunits. Indeed, rodent can express six different
c-secretases, whereas only four human c-secretases can be
assembled. Apart from PS1 and PS2, human cells express two
Aph1 subunits (A and B), whereas the duplication of the Aph1B
gene in rodents gives rise to a third Aph1 protein (Aph1C). A
very recent study indicated that trafficking of the c-secretase
complex depends on the Aph1 variant expressed in the cells
[16]. Thus, catalytic properties of the c-secretase and specificity
towards the processing of a particular substrate depend on both
its subunit composition and subcellular localization. This is con-
firmed by our results, showing differential effects of pharmaco-
logical inhibitors on c-secretase containing either human or
murine PS1 and PS2. But very importantly, it also indicates that
results of c-secretase inhibitors tested in mice models cannot be
directly extrapolated to human c-secretases. This point is critical
for trials evaluating the therapeutic interest of small molecules
targeting the c-secretase, which have been unsuccessful so far.
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Supplementary FigS1. Expression of C99-GVP and NotchE-GVP in PS+/+
transfected cells. Cell lysates were analyzed by Western blotting using an antibody
directed against the VP16 domain of the GVP fusion protein. Tubulin served as a
loading control. Cells transfected with either C99-GVP (A) or NotchE-GVP (B)
exhibit bands at the expected molecular weights (indicated by arrows), which are


































































Supplementary FigS2. Effect of γ-secretase inhibitors on endogenous APP and
Notch CTFs accumulation. All MEFs were plated in 6-well plates and treated 24h
after seeding with either DAPT 10M or L-685 10M. Cells were harvested 16h
after treatment for Western blotting. PS+/+ and PSdKO were used as positive and
negative controls of substrates cleavage, respectively. APP-CTF (A) and NotchE
(B) were detected using specific antibodies targeting the C-terminal regions of the
full-length APP and Notch proteins. Expected positions of APP CTF and NotchE



















































Supplementary Figure S2 
Supplementary Figure S3 
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PS1 PS1PS2 PS2
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B
Supplementary FigS3. Immunocytochemical characterization of PS1 and PS2 subcellular
localization in knockout and rescued models. Cells were fixed with 4% paraformaldehyde (PFA)
in PBS and immuno-stained for PS1 or PS2 (red) and DAPI (blue). Stainings have been analyzed by
confocal microscopy to generate z-stack images. Endogenously expressed PSs (A) and human PSs
isoforms stably re-expressed by lentiviral infection (B) show an identical distribution in the cell.
Scale: 20μm.
Supplementary Table1. Details of DAPT and L-685 inhibitory effect on murine and 
human PSs cleavage activity in MEFs cells transfected with exogenous substrates. Cells 
were transfected with either C99-GVP or NotchΔE-GVP construct and with reporter genes, 
were treated with DAPT 250nM, 1µM, 10µM or L-685 10µM, 20µM for 16h and were 
quantified for AICD-GVP or NICD-GVP production using the Dual-Glo
®
 Luciferase Assay 
System. NI stands for “no inhibition”. *p<0.05, **p<0.01, ***p<0.001 vs corresponding NT 
cell type, n=9 in 3 independent experiments. 
 








DAPT 250nM 2.86 19.31 54.30*** 15.25 40.92* NI 21.46 12.65 
DAPT 1µM 26.19 22.84 61.40*** 31.93** 47.10** NI 26.29 29.04 
DAPT 10µM 30.24 NI 65.85*** 24.94 42.15** 17.86 43.01 31.58 
L-685 10µM 16.21 NI 59.24*** 26.11 49.39*** NI 27.32 16.88 










 DAPT 250nM 29.13 NI 77.08*** NI 49.72*** NI 50.28*** 40.53 
DAPT 1µM 32.32** 22.77 79.60*** 6.48 58.19*** NI 35.70* 4.77 
DAPT 10µM 44.90** NI 78.82*** 20.91 60.40*** 17.79 54.62*** 22.12 
L-685 10µM 46.12*** NI 73.92*** 16.87 67.82*** 1.72 45.71** NI 
L-685 20µM 65.46*** NI 85.91*** 45.30 66.34*** 2.38 54.70*** 5.73 
 
 
 
